• Sign In
  • FAQ
  • Create an Account
  • 866-930-6790
Currency
USD
Toggle Nav
My Cart
Search
Menu
Account
Settings
Currency
USD
  • Home
  • Protein Tyrosine Kinases

Protein Tyrosine Kinases

Shop By
Clear All

Items 151-200 of 544

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. A11962
    TG-02 (SB1317)

    FLT3 inhibitor

    TG-02 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor.
    Quick View
  2. A12005
    Sorafenib N-Oxide

    Raf kinase inhibitor

    Sorafenib N-Oxide is a metabolite of Sorafenib, a potent Raf kinase inhibitor.
    Quick View
  3. A12008
    AZ7550

    IGF1R inhibitor

    AZ7550 is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM.
    Quick View
  4. A12214
    KX1-004

    Src-PTK inhibitor

    KX1-004 is a potent small molecule inhibitor of Src-PTK as a potential protective drug for NIHL.
    Quick View
  5. A12299
    Src Inhibitor 1

    Src tyrosine kinase inhibitor

    Src Inhibitor 1 is a potent and selective dual site Src tyrosine kinase inhibitor with IC50 values of 44 nM for Src and 88nM for Lck.
    Quick View
  6. A12357
    FIIN-2

    FGFR Inhibitor

    FIIN-2 is an irreversible inhibitor of FGFR1-4 with IC50 values of 3.1, 4.3, 27, and 45 nM, respectively.
    Quick View
  7. A12358
    A 83-01

    TGF-β/ALK5 inhibitor

    A83-01 is a selective inhibitor of the transforming growth factor-beta type I receptor ALK5, the Nodal receptor ALK4, and the nodal receptor ALK7
    Quick View
  8. A12419
    Go 6976

    PKC inhibitor

    Go6976 is a potent PKC inhibitor with IC50 of 7.9 nM, 2.3 nM, and 6.2 nM for PKC (Rat brain), PKCα, and PKCβ1, respectively. Also a potent inhibitor of JAK2 and Flt3.
    Quick View
  9. A12421
    CHMFL-ABL/KIT-155

    ABL/c-KIT dual kinase inhibitor

    CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor.
    Quick View
  10. A12427
    TCS 359

    FLT3 inhibitor

    TCS 359 is a potent inhibitor of FLT3 receptor tyrosine kinase (IC50 = 42 nM) that displays selectivity over a range of other kinases.
    Quick View
  11. A12437
    SU 5416 (Semaxinib)

    VEGFR Inhibitor

    SU 5416 is an inhibitor of vascular endothelial growth factor receptor (VEGFR) that also inhibits other tyrosine kinases KIT, MET, FLT3 and RET.
    Quick View
  12. A12472
    SU1498

    VEGFR2 inhibitor

    SU1498 is a selective inhibitor of the VEGFR2; inhibits Flk-1 with an IC50 of value of 700 nM.
    Quick View
  13. A12484
    GENZ-882706

    CSF-1R Inhibitor

    GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor extracted from patent WO 2017015267A1.
    Quick View
  14. A12486
    Tyrosine kinase-IN-1

    multi-targeted tyrosine kinase inhibitor

    Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC50s of 4, 20, 4, 2 nM for KDR, Flt-1, FGFR1 and PDGFRα, respectively.
    Quick View
  15. A12488
    c-met-IN-1

    c-Met inhibitor

    c-met-IN-1 (compound 16) is a potent and selective c-Met inhibitor, with IC50 of 1.1 nM, with antitumor activity.
    Quick View
  16. A12493
    ALW-II-41-27

    Eph receptor inhibitor

    ALW-II-41-27 is a novel Eph receptor tyrosine kinase inhibitor.
    Quick View
  17. A12524
    CHMFL-EGFR-202

    EGFR inhibitor

    CHMFL-EGFR-202 is a potent, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant kinase, with IC50s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively.
    Quick View
  18. A12557
    LY2801653 (Merestinib)

    c-MET inhibitor

    LY2801653 is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase(Ki= 2 nM).
    Quick View
  19. A12628
    EGFR-IN-2

    EGFR inhibitor

    EGFR-IN-2 is a a noncovalent, irreversible, mutant-selective second generation EGFR inhibitor.
    Quick View
  20. A12650
    PKC 412 (Midostaurin)

    PKC inhibitor

    PKC 412 is a broad spectrum protein kinase inhibitor. Inhibits conventional PKC isoforms α/β/γ, PDFRβ, VEGFR2, Syk, Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEGFR1 and EGFR. Displays potent antitumor activity.
    Quick View
  21. A12666
    AZ 23

    TrkA inhibitor

    AZ 23 is a potent and selective tyrosine kinase Trk inhibitor with IC50 to 2 and 8 nM for TrkA and TrkB respectively
    Quick View
  22. A12687
    JNJ-28312141

    CSF1R inhibitor

    JNJ-28312141 is an orally active CSF1R inhibitor (Colony-stimulating factor-1 receptor, CRF1R) and also a FLT3 inhibitor. CSF1R is expressed by many tumors and is a growth factor for macrophages and mediates osteoclast differentiation. JNJ-28312141 represents a new agent with potential therapeutic activity in acute myeloid leukemia and in settings where CSF-1-dependent macrophages and osteoclasts contribute to tumor growth and skeletal events.
    Quick View
  23. A12693
    NVP-BAW2881

    VEGFR inhibitor

    NVP-BAW2881 is a potent and selective VEGFR inhibitor (vascular endothelial growth factor receptor tyrosine kinase inhibitor) with activity to inhibit chronic and acute skin inflammation.
    Quick View
  24. A12694
    Pacritinib (SB1518)

    JAK2/FLT3 inhibitor

    Pacritinib, also known as SB1518, is an orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Pacritinib competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis.
    Quick View
  25. A12723
    PP2

    Src Inhibitor

    PP2 is a selective inhibitor of Src-family tyrosine kinases. Inhibits p56lck and p59fynT (IC50 values are 4 and 5 nM respectively). Displays > 10000-fold selectivity over ZAP-70 and JAK2. Moderately inhibits CSK (IC50 = 0.73 μM).
    Quick View
  26. A12724
    PP1

    Src Inhibitor

    PP1 is a potent inhibitor of Src-family tyrosine kinases. Inhibits p56lck and p59fynT (IC50 values are 5 and 6 nM respectively). Displays > 8000-fold selectivity over ZAP-70 and JAK2. Also moderately inhibits p38, CSK, PDGF receptors, RET-derived oncoproteins, c-Kit and Bcr-Abl
    Quick View
  27. A12725
    PD168393

    EGFR inhibitor

    PD168393 is a potent, cell-permeable, irreversible inhibitor of EGFR with IC50 value of 700 pM.
    Quick View
  28. A12820
    DMH-1

    ALK2 inhibitor

    DMH-1 is a selective inhibitor of the bone morphogenic protein (BMP) ALK2 receptor (IC50 = 108 nM).
    Quick View
  29. A12867
    CGP-52411

    EGFR inhibitor

    CGP-52411 is a slective inhibitor of the epidermal growth factor receptor (EGFR) (IC50 = 0.3 μM in vitro). Also inhibits and reverses the formation of Aβ42 fibers associated with Alzheimer's disease.
    Quick View
  30. A12868
    Varlitinib tosylate (ASLAN001 tosylate, ARRY-334543 tosylate)

    ErbB inhibitor

    ARRY-543 is a novel, oral ErbB family inhibitor that, unlike approved ErbB inhibitors, targets all members of the ErbB family, including ErbB3, either directly or indirectly, and has potential advantages in treating tumors that signal through multiple ErbB family members.
    Quick View
  31. A12955
    DDR-TRK-1

    DDR1 inhibitor

    DDR-TRK-1 is a selective Discoidin Domain Receptor 1 (DDR1) inhibitor, with an IC50 value of 9.4 nM. DDR-TRK-1 also inhibits TRK family.
    Quick View
  32. A13001
    AG-1517

    EGFR inhibitor

    AG 1517 is a potent and selective ATP competitive inhibitor of the epidermal growth factor receptor tyrosine kinase EGFR.
    Quick View
  33. A13003
    LDC1267

    TAM Receptor inhibitor

    LDC1267 is a highly selective TAM(Tyro3, Axl and Mer) kinase inhibitor with IC50 of <5 nM/8 nM/29 nM for Tyro3,Axl and Mer respectively.
    Quick View
  34. A13008
    Edicotinib

    CSF-1 receptor inhibitor

    Edicotinib is a selective and orally available colony-stimulating factor-1 (CSF-1) receptor inhibitor, and has entered phase IIA clinical trial to study rheumatoid arthritis (RA) despite disease.
    Quick View
  35. A13028
    CO-1686 (Rociletinib, AVL-301)

    EGFR inhibitor

    CO-1686 is a novel, oral, targeted covalent (irreversible) inhibitor of the cancer-causing mutant forms of epidermal growth factor receptor (EGFR) currently being studied for the treatment of non-small cell lung cancer (NSCLC).
    Quick View
  36. A13044
    Poziotinib

    EGFR inhibitor

    Poziotinib is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity.
    Quick View
  37. A13065
    AZD3463

    ALK/IGF1R inhibitor

    AZD-3463 is a ALK/IGF1R inhibitor.
    Quick View
  38. A13069
    XL-228

    IGF-1R, Aurora, FGFR, ABL, SRC inhibitor

    XL228 is a protein kinase inhibitor targeting IGF1R, the AURORA kinases, FGFR1-3, ABL and SRC family kinases. XL228 is an Aurora A inhibitor (IC50, f3 nmol/L) that has shown potent biochemical activity against ABL1 (Ki, 5 nmol/L), as well as the BCR-ABL1 T315I (Ki, 1.4 nmol/L) kinases.
    Quick View
  39. A13111
    R1530

    Chk2, KDR, FGFR, Aurora A & Cdk2 inhibitor

    R1530 is a pyrazolobenzodiazepine small molecule with potential antiangiogenesis and antineoplastic activities. R1530 is also a mitosis-angiogenesis inhibitor (MAI) that inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor (PDGFR) beta? FMS-like tyrosine kinase (Flt)-3, and fibroblast growth factor receptor (FGFR) -1, -2.
    Quick View
  40. A13126
    eCF506

    Src inhibitor

    eCF506 is a highly potent and orally bioavailable inhibitor of the non-receptor tyrosine kinase Src with an IC50 of less than 0.5 nM.
    Quick View
  41. A13146
    CL-387785 (EKI-785)

    EGFR inhibitor

    CL-387785 is an irreversible inhibitor of EGFR with IC50 of 370+/-120 pM; is able to overcome resistance caused by the T790M mutation on a functional level.
    Quick View
  42. A13167
    AMG-47a

    Lck inhibitor

    AMG-47a is an orally bioavailable potent inhibitor of Lck and T cell proliferation. It exhibits anti-inflammatory activity (ED50 11 mg/kg) in the anti-CD3 induced production of IL-2 in mice.
    Quick View
  43. A13211
    SSR128129E

    FGFR1 inhibitor

    SSR128129E is an orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 uM
    Quick View
  44. A13232
    1-NA-PP1

    Src Kinase inhibitor

    1-NA-PP1 is a selective inhibitor of v-Src and c-Fyn as well as c-Abl
    Quick View
  45. A13234
    SKLB1002

    VEGFR inhibitor

    SKLB1002 is a new potent VEGFR2 inhibitor, which could significantly inhibit HUVEC proliferation, migration, invasion, and tube formation.
    Quick View
  46. A13238
    Ceritinib (LDK-378)

    ALK Inhibitor

    LDK378 is a highly selective, orally bioavailable and ATP-competitive small molecule inhibitor of ALK (Anaplastic Lymphoma Kinase), a receptor tyrosine kinase considered to be an important lung cancer drug target.
    Quick View
  47. A13240
    NVP-ACC789

    VEGFR-2 inhibitor

    NVP-ACC789 is an inhibitor of VEGFR-2 (FLK-1/KDR).
    Quick View
  48. A13290
    A-419259

    SFK inhibitor

    A-419259 trihydrochloride is an inhibitor of Src family kinases (SFK) (IC50 = 0.1 - 0.3 uM).
    Quick View
  49. A13377
    SAR131675

    VEGFR3 Inhibitor

    SAR131675, a potent and selective VEGFR-3-TK inhibitor with antilymphangiogenic, antitumoral, and antimetastatic activities.
    Quick View
  50. A13450
    Brigatinib (AP26113)

    ALK Inhibitor

    Brigatinib (AP26113) is a potent and selective ALK (IC50, 0.6 nM) and ROS1 (IC50, 0.9 nM) inhibitor. It also inhibits ROS1, FLT3, and mutant variants of FLT3 (D835Y) and EGFR with lower potentcy.
    Quick View

Items 151-200 of 544

Page
per page
Set Descending Direction
Shop By
Now Shopping by
  1. Actions
    Inhibitor
Clear All
Shopping Options
Category
On sale
  1. Yes 1 item
Price
  1. $0.00 - $1,000.00 540 items
  2. $1,000.00 - $2,000.00 3 items
  3. $5,000.00 - $6,000.00 1 item